Skip to main content
Trending
Corporate earningsAi infrastructureEnergy marketsElection litigationAviation safetyCrypto securityAi governanceEnterprise aiPlatform liabilityAvian influenzaClinical trialsFederal debtPresidential runoffRpg developmentSpace debrisAir defenseAutonomous vehiclesBudget crisisBug bountiesEnergy m&aForeign investmentFranchise restructuringGene therapyPandemic treatyTranslation pathwaysUn peacekeepingWeapons testingWeight-space programmingAi copyright lawArchaeological toxicology

full timeline

Phase 3 Trial Shows Psychedelic-Derived DT120 Achieves Rapid Remission for Generalized Anxiety Disorder

A single-dose formulation of LSD has met its primary endpoints in a second Phase 3 clinical trial, demonstrating rapid and sustained symptom relief for patients with generalized anxiety disorder. The results position the psychedelic compound as the first potentially new pharmacological mechanism for the condition in over two decades.

Factlen Newsroom· Updated

Follow Phase 3 Trial Shows Psychedelic-Derived DT120 Achieves Rapid Remission for Generalized Anxiety Disorder in the Factlen app and get an alert when there is news. Get the app

The DT120 protocol involves a single supervised dosing session rather than daily medication.From: Definium Therapeutics' Single-Dose LSD Therapy Clears Second Phase 3 Trial for Generalized Anxiety Disorder

Share this story

Key numbers

62%
Patients achieving clinical remission at week 4
14 days
Median time to significant symptom reduction
0
Reported cases of hallucinogenic side effects
412
Participants in the Phase 3 trial

From: Phase 3 Trial Shows Psychedelic-Derived DT120 Achieves Rapid Remission for Generalized Anxiety Disorder

Charts, maps and images

Key efficacy and safety metrics from the 412-patient Phase 3 trial.From: Phase 3 Trial Shows Psychedelic-Derived DT120 Achieves Rapid Remission for Generalized Anxiety Disorder ·
Patients receiving DT120 saw significant symptom reduction within the first two weeks of treatment.From: Phase 3 Trial Shows Psychedelic-Derived DT120 Achieves Rapid Remission for Generalized Anxiety Disorder ·
Definium Therapeutics is testing the LSD-based compound as a single-dose treatment.From: Definium Therapeutics' Single-Dose LSD Therapy Clears Second Phase 3 Trial for Generalized Anxiety Disorder ·
The compound met its primary endpoints in its second Phase 3 trial.From: Definium Therapeutics' Single-Dose LSD Therapy Clears Second Phase 3 Trial for Generalized Anxiety Disorder ·

Timeline

September 2026

  1. Definium Therapeutics' Single-Dose LSD Therapy Clears Second Phase 3 Trial for Generalized Anxiety Disorder

August 2026

  1. Phase 3 Trial Shows Psychedelic-Derived DT120 Achieves Rapid Remission for Generalized Anxiety Disorder